Journal of refractive surgery (Thorofare, N.J. : 1995) · 2017
Outcomes of Toric Iris-Claw Phakic Intraocular Lens Implantation After Deep Anterior Lamellar Keratoplasty for Keratoconus.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tiveron Mauro C, Alió Del Barrio Jorge L, Kara-Junior Newton, Plaza-Puche Ana Belén, Abu-Mustafa Sabat K, Zein Ghassan, Alió Jorge L
Аннотация
PURPOSE: To assess visual and refractive outcomes of toric iris-claw phakic intraocular lens (IOL) implantation in patients who had previously undergone deep anterior lamellar keratoplasty (DALK).
METHODS: Retrospective case series including 24 eyes of 24 patients implanted with toric Artiflex or Artisan (Ophtec BV, Groningen, Holland) phakic IOL following DALK for keratoconus. During a 12-month follow-up, the main outcome measures were uncorrected and corrected distance visual acuities (UDVA and CDVA), refractive error components, topographic parameters, and endothelial cell count. Alpins vectorial analysis was performed.
RESULTS: At the last follow-up, the spherical equivalent (SE) was within ±0.50 diopters (D) in 71% of eyes and within ±1.00 D in 92% of eyes. Mean refractive astigmatism was reduced from -4.92 ± 1.55 D (range: -2.50 to -8.00 D) preoperatively to -0.66 ± 0.61 D (range: -2.00 to 0.00 D) after treatment, and 76.5% of cases were within ±1.00 D. No significant differences (P = .123) were detected in spherical equivalent values between 3- and 12-month follow-up visits. No eyes lost lines in CDVA, and 54% of eyes gained one or more lines. Postoperative UDVA was 20/40 or better in 88% of eyes. Efficacy and safety indexes at 12 months were 0.93 and 1.00, respectively. Mean endothelial cell loss was 6.10% at 12 months postoperatively. No intraoperative or postoperative complications were noted over the follow-up period.
CONCLUSIONS: The implantation of a toric iris-claw phakic IOL has shown high efficacy and safety in this series and may be considered as a reasonable option for the management of refractive errors after DALK. [J Refract Surg. 2017;33(8):538-544.].
METHODS: Retrospective case series including 24 eyes of 24 patients implanted with toric Artiflex or Artisan (Ophtec BV, Groningen, Holland) phakic IOL following DALK for keratoconus. During a 12-month follow-up, the main outcome measures were uncorrected and corrected distance visual acuities (UDVA and CDVA), refractive error components, topographic parameters, and endothelial cell count. Alpins vectorial analysis was performed.
RESULTS: At the last follow-up, the spherical equivalent (SE) was within ±0.50 diopters (D) in 71% of eyes and within ±1.00 D in 92% of eyes. Mean refractive astigmatism was reduced from -4.92 ± 1.55 D (range: -2.50 to -8.00 D) preoperatively to -0.66 ± 0.61 D (range: -2.00 to 0.00 D) after treatment, and 76.5% of cases were within ±1.00 D. No significant differences (P = .123) were detected in spherical equivalent values between 3- and 12-month follow-up visits. No eyes lost lines in CDVA, and 54% of eyes gained one or more lines. Postoperative UDVA was 20/40 or better in 88% of eyes. Efficacy and safety indexes at 12 months were 0.93 and 1.00, respectively. Mean endothelial cell loss was 6.10% at 12 months postoperatively. No intraoperative or postoperative complications were noted over the follow-up period.
CONCLUSIONS: The implantation of a toric iris-claw phakic IOL has shown high efficacy and safety in this series and may be considered as a reasonable option for the management of refractive errors after DALK. [J Refract Surg. 2017;33(8):538-544.].